Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

Kronos Bio, Inc. Common Stock (KRON)

Pharmaceutical Preparations

https://www.kronosbio.com

Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.

1300 S. EL CAMINO REAL, SUITE 400
SAN MATEO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/09/2020

Market Cap

59,499,465

Shares Outstanding

58,320,000

Weighted SO

58,316,520

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

CYCN --.--%

LRMR --.--%

ADXN --.--%

ACHL --.--%

NXTC --.--%

CTMX --.--%

NLTX --.--%

SPRO --.--%

ASMB --.--%

Beta

1.8930

Last Div

0.0000

Range

0.69-1.6

Chg

0.0025

Avg Vol

371551

Mkt Cap

59499465

Exch

NASDAQ

Country

US

Phone

650 781 5200

DCF Diff

0.0035

DCF

0.9867

Div Yield

0.0000

P/S

7.0740

EV Multiple

-0.1717

P/FV

0.4832

Div Yield %

0.0000

P/E

-0.5785

PEG

-0.0380

Payout

0.0000

Current Ratio

8.4852

Quick Ratio

8.4852

Cash Ratio

4.2194

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

134.8321

CCC

-134.8321

Gross Margin

0.6814

Op Margin

-11.6302

Pretax Margin

-12.2283

Net Margin

-12.2283

Eff Tax Rate

-0.0394

ROA

-0.6261

ROE

-0.6882

ROCE

-0.6626

NI/EBT

1.0000

EBT/EBIT

1.0514

EBIT/Rev

-11.6302

Debt Ratio

0.1652

D/E

0.2203

LT Debt/Cap

0.1603

Total Debt/Cap

0.1805

Int Coverage

-6.1756

CF/Debt

-3.2375

Equity Multi

1.3340

Rec Turnover

0.0000

Pay Turnover

2.7071

Inv Turnover

0.0000

FA Turnover

0.4106

Asset Turnover

0.0512

OCF/Share

-1.4616

FCF/Share

-1.4657

Cash/Share

2.2737

OCF/Sales

-10.4433

FCF/OCF

1.0029

CF Coverage

-3.2375

ST Coverage

-24.2783

CapEx Coverage

-348.5675

Div&CapEx Cov

-348.5675

P/BV

0.4832

P/B

0.4832

P/S

7.0740

P/E

-0.5785

P/FCF

-0.6754

P/OCF

-0.6774

P/CF

-0.6774

PEG

-0.0380

P/S

7.0740

EV Multiple

-0.1717

P/FV

0.4832

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 18, 22:41 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders GlobeNewswire Inc. May 17, 17:00 $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – PRA, KRON, AXL, SWTX Benzinga May 16, 22:30 STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - PRA, KRON, AXL, SWTX GlobeNewswire Inc. May 15, 22:52 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders GlobeNewswire Inc. May 03, 20:37 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNB, COLB, KRON on Behalf of Shareholders Benzinga Dec 19, 13:47 Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study Benzinga Dec 19, 13:47 Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study Benzinga Dec 19, 07:30 Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday GlobeNewswire Inc. Nov 27, 16:05 Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference PennyStocks Nov 20, 10:17 Best Penny Stocks To Buy This Week? 4 To Watch Now GlobeNewswire Inc. Nov 02, 12:00 Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting GlobeNewswire Inc. Oct 13, 12:30 Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

Revenue Product Segmentation